WEBULL
WebtradeDownload

How First Phase 1 MS Data Will Impact TG Therapeutics Stock (TGTX)

Simply Wall St · 2d ago
  • TG Therapeutics reported initial Phase 1 data for azer-cel, its allogeneic CD19-directed CAR T-cell therapy, in progressive multiple sclerosis. This marks the first clinical evaluation of this type of treatment in this setting.
  • The azer-cel update highlights TG Therapeutics' effort to expand its autoimmune footprint beyond BRIUMVI by incorporating a mechanistically distinct cell therapy approach.
  • The focus now turns to how TG Therapeutics' investment narrative could evolve as azer-cel introduces a new potential path in progressive multiple sclerosis.

Scan how TG Therapeutics fits within a broader push in autoimmune and multiple sclerosis treatments by reviewing the hand picked list of 35 healthcare AI stocks.

TG Therapeutics Investment Narrative Recap

For TG Therapeutics, the big picture is simple. You need to believe BRIUMVI can support a durable autoimmune franchise while new modalities like azer cel add credible depth rather than distraction. The near-term story still leans on execution in multiple sclerosis, cost discipline and converting high gross margins into cleaner cash generation.

The azer cel Phase 1 update is important scientifically but does not immediately change the key near-term catalyst, which remains subcutaneous BRIUMVI and related label work. The biggest current risk stays the same, that heavy manufacturing and development spending, plus any governance overhang, keeps pressuring earnings quality and free cash flow.

With no fresh corporate announcements tied directly to the azer cel readout, the most relevant prior milestone remains the fully enrolled Phase 3 program for subcutaneous BRIUMVI, backed by Phase 1 data showing around 60% bioavailability and acceptable injection tolerability. That program targets a self-administered MS segment TG Therapeutics does not currently reach.

If subcutaneous BRIUMVI eventually launches alongside any future label simplification based on ENHANCE, TG Therapeutics would be trying to serve both infusion and self-administered anti-CD20 demand. Execution on that shift, while keeping manufacturing investments under control, is the operational hinge for how much the current BRIUMVI cash engine can support newer assets like azer cel.

TG Therapeutics' current analyst narrative points to revenues of US$1.8b and earnings of US$619.2 million by 2029, anchored on an assumed 30.2% yearly revenue growth rate. That path implies earnings rising by about US$177.7 million from US$441.5 million today to the 2029 consensus level.

Discover why TG Therapeutics' fair value signals a 17% potential upside to its current price, an opportunity that could narrow quickly.

NasdaqCM:TGTX 1-Year Stock Price Chart
NasdaqCM:TGTX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate view on TG Therapeutics leans hard into azer cel as a future growth engine. The most optimistic analysts were already penciling in around US$2.2b of revenue and US$761.4 million of earnings by 2029 before this data, so you can see how opinions stretch. Use this update as a prompt to compare several narratives.

Explore 4 other TG Therapeutics fair value estimates, including one that suggests a potential 189% increase from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.

Looking For More Investment Ideas Beyond TG Therapeutics?

If you want to put TG Therapeutics in context and line it up against other opportunities, the Simply Wall St Screener can help you cast a wider net without drowning in data.